AU Patent
AU2017342022A1 — Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Assigned to Array Biopharma Inc · Expires 2019-05-23 · 7y expired
What this patent protects
Provided herein are compounds of the Formula I and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X
USPTO Abstract
Provided herein are compounds of the Formula I and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X
Drugs covered by this patent
- Retevmo (SELPERCATINIB) · Eli Lilly
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.